Evidence map›Paper›PMID 37776124›Full record

ArticleJournal of managed care & specialty pharmacy2023

Comparison of health care costs and resource utilization for commonly used proteasome inhibitor-immunomodulatory drug-based triplet regimens for the management of patients with relapsed/refractory multiple myeloma in the United States.

Larysa Sanchez, Ajai Chari, Mu Cheng, Dasha Cherepanov, Maral DerSarkissian, Fei Huang, Dawn Marie Stull, Jonathan Dabora, Melanie Young, Stephen J Noga and 5 more

Erratum issuedOpen access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of managed care & specialty pharmacy, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.9field-weighted citation impact, top 22% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 3 citations in OpenAlex.

  1. Observational
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

15 authors at 4 institutions in 1 country.

Larysa SanchezIcahn School of Medicine at Mount Sinai, New York, NY.
Ajai ChariIcahn School of Medicine at Mount Sinai, New York, NY.
Mu ChengAnalysis Group, Inc., Boston, MA.
Dasha CherepanovTakeda Development Center Americas, Lexington, MA.
Maral DerSarkissianAnalysis Group, Inc., Boston, MA.
Fei HuangTakeda Development Center Americas, Lexington, MA.
Dawn Marie StullTakeda Development Center Americas, Lexington, MA.
Jonathan DaboraTakeda Development Center Americas, Lexington, MA.
Melanie YoungTakeda Development Center Americas, Lexington, MA.
Stephen J NogaTakeda Development Center Americas, Lexington, MA.
Selina PiAnalysis Group, Inc., Boston, MA.
Melody ZhangAnalysis Group, Inc., Boston, MA.
Azeem BanatwalaAnalysis Group, Inc., Boston, MA.
Mei Sheng DuhAnalysis Group, Inc., Boston, MA.
Sikander AilawadhiMayo Clinic, Jacksonville, FL.
Analysis Group (United States) · USTakeda (United States) · USIcahn School of Medicine at Mount Sinai · USWinnMed · US

Funding

AHRQ HHS T32 HS000046
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Multiple MyelomaAdultHealth Care CostsHumansLongitudinal StudiesProteasome InhibitorsRetrospective StudiesUnited StatesProteasome Inhibitors

Identifiers

PMID37776124
PMCPMC10776283
OpenAlexW4387210061

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.